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In patients with diabetic nephropathy, lowering blood
pressure and reducing proteinuria by over 30% correlates
with a slower progression to kidney failure. We compared
two different angiotensin receptor-blockers in a double blind,
prospective trial of 860 patients with type 2 diabetes whose
blood pressure levels was over 130/80 mmHg or who were
receiving antihypertensive medication(s) and who had a
morning spot urinary protein to creatinine ratio of 700 or
more. Patients were randomized to telmisartan (a highly
lipophilic agent with a long half-life) or losartan (with low
lipophilicity and short half-life). The primary endpoint was
the difference in the urinary albumin to creatinine ratio
between the groups at 52 weeks. The geometric coefficient
of variation and the mean of the urinary albumin to
creatinine ratio fell in both groups at 52 weeks but both were
significantly greater for the telmisartan compared to the
losartan cohort. Mean systolic blood pressure reductions
were not significantly different between groups at trial end.
We conclude that telmisartan is superior to losartan in
reducing proteinuria in hypertensive patients with diabetic
nephropathy, despite a similar reduction in blood pressure.
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Proteinuric kidney disease is a frequent complication of
diabetes, the most common cause of kidney failure in the
western world,1 and results in reduced life expectancy.2 Post
hoc analyses of renal outcome trials demonstrate that a
430% reduction in proteinuria at 6 months correlates with
slowed progression of kidney disease.3–6 Uncontrolled
hypertension contributes to increases in proteinuria, and
blood pressure control is associated with reduced urinary
protein excretion and slowed decline in renal function.7
Achievement of a target blood pressure, that is, o130/
80 mm Hg, in patients with proteinuria, using a blocker of
the rennin–angiotensin system as part of the regimen, is
recommended by current guidelines.8–10 The current trial
tests the hypothesis that a highly lipophilic11 angiotensin-
receptor blocker (ARB) with a long half-life will yield
relatively greater antiproteinuric effects at similar levels of
blood pressure control compared with one that has a shorter
half-life and low lipophilicity.
RESULTS
This prospective, randomized, double-blind, double-dummy,
forced-titration, multicenter, parallel-group, study compared
telMisartan (80 mg) vs losArtan (100 mg) in hypertensive
type-2 DiabEtic patients with Overt nephropathy. It was
conducted at 124 centers in Argentina, Australia, Brazil,
Canada, Mexico, New Zealand, South Korea, Taiwan, Thai-
land, and the United States, with 1,567 outpatients meeting
inclusion criteria and 860(55%) randomized to treatment
(Table 1). There were many reasons for people not being
randomized and most dealt with problems related to
duration of follow-up and frequency of visits. Eighty percent
of the total cohort completed the trial, 345 and 342 patients
in the telmisartan and losartan groups, respectively. The
mean duration of follow-up for the entire cohort was 324.25
days.
Primary endpoint
Although each agent reduced adjusted mean urinary protein-
to-creatinine (UPC) significantly (29.8% telmisartan
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(Po0.0001) and 21.4% losartan (Po0.0001)), the reduction
in UPC from baseline was greater for telmisartan (P¼ 0.03;
Figure 1), thus achieving the primary endpoint.
Secondary endpoints
Table 2 summarizes secondary endpoints. In the telmisartan
group, the geometric mean urinary albumin:creatinine was
reduced from 1426.1 mg/g to 952.5 mg/g creatinine
(Po0.0001). In the losartan group, the corresponding values
for baseline and end of treatment were 1,390.5 and
1,054.9 mg/g creatinine (Po0.0001). This translated into a
35.5% greater reduction with telmisartan vs 27.0% with
losartan (P¼ 0.04). These between-proteinuria differences
could not be accounted for by differences in sodium intake
throughout the trial (Figure 2).
Changes in blood pressure are shown in Figure 3. Both
groups had significant reductions in diastolic pressure at trial
end, with no differences between groups (3.3±0.6, telmi-
sartan vs 2.9±0.6, losartan; P¼ 0.61). Systolic pressure also
failed to show consistent difference throughout the study
(Figure 3). There was a trend in favor of telmisartan on the
day-56 time point, where a 4.2-mm Hg difference was present
favoring telmisartan, although much smaller differences were
seen at all other time points throughout the remainder of the
study (Figure 3). Note that during the initial washout period,
all patients had their angiotensin-converting enzyme inhibi-
tors (47.3%, telmisartan and 43.8% losartan groups) and
ARBs (20.5% telmisartan and 23.8% losartan groups)
stopped. Antihypertensive agents that were continued into
the randomized phase included calcium-channel blockers
(71.5%), thiazide diuretics (64.7%), and b-blockers (47.0%).
Note that more than 80% of the calcium-channel blockers
were in the dihydropyridine subclass and there were no
differences in use between the groups. Other agents
continued into the randomized phase were oral antidiabetic
agents (66.0%), statins (56.9%), and insulin (47.3%), with no
differences in use between treatment groups. Moreover,
during the trial agents that were added to achieve blood
pressure or metabolic control to those receiving only
randomized drugs included dihydropyridine calcium-chan-
nel blockers (76.4%), diuretics (74.2%), b-blockers (53.5%),
oral antidiabetic agents (70.5%), statins (64.5%), and insulin
(54.3%), with no differences between treatment groups.
There were no between-group differences in the time to
first event for the secondary composite endpoints of doubling
of serum creatinine, end-stage renal disease, and all-cause
death (14 events (3.4%), telmisartan vs 25 events (5.9%),
losartan; P¼ 0.083). The composite renal endpoint alone was
not different between the groups. A between-group difference
for the composite of cardiovascular morbidity or mortality,
however, was noted (21 events, telmisartan vs 37 events,
losartan; P¼ 0.037). All-cause death was also different
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P=0.027
Figure 1 | Changes in UPC in each group. The values represent
mean±s.d.s at each time point.






Age (years) 60.0±9.2 60.5±9.4
o65 years (%) 66.8 62.1






Mean±s.d. BMI (kg/m2) 30.1±6.8a 29.9±6.2b
Current smokers (%) 15.0 16.1












1970.9 (100.8%)e 2010.5 (104.5%)f
Urinary albumin:creatinine
(mg/g creatinine)++
1400.8 (118.0%)g 1387.0 (126.0%)h
Urinary sodium:creatinine
(mmol/g creatinine)++
72.4 (95.1%)e 76.7 (88.4%)h
Serum creatinine (mg/dl)++ 1.54 (40.6%) 1.55 (41.2%)
eGFR (ml/min/1.73 m2) 49.5±21.6 49.6±22.4
Serum aldosterone (ng/dl)++ 7.6 (91.9%)i 7.1 (90.8%)j
C-reactive protein (mg/l)++ 2.2 (209.5%)a 2.4 (197.9%)b
SBP (mm Hg) 143.7±15.7 143.2±15.4
DBP (mm Hg) 79.9±9.4 79.5±9.6
Hemoglobin A1c (%) 7.9±1.3g 7.9±1.3h
AMADEO, a prospective, randomized, double-blind, double-dummy, forced-titration,
multicenter, parallel-group, 1-year treatment trial to compare telMisartan (80 mg) vs
losArtan (100 mg) in hypertensive type-2 DiabEtic patients with Overt nephropathy;
BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular
filtration rate; gCV, geometric mean of variation; gMean, geometric mean; SBP,
systolic blood pressure; s.d., standard deviation.
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Safety
Adverse events were experienced by 84% of the telmisartan-
group patients and 82.1% of the losartan-group patients.
Severe events were recorded in 15.5% of the telmisartan- and
22.4% of the losartan-group patients. Hyperkalemia was rare
in the study, with 1.8% of the total cohort having a serum
potassium level of 45.5 mEq/l. There were six discontinua-
tions in each group due to treatment-related adverse events.
During the study, 25 patients died, but no death was
considered study drug-related.
DISCUSSION
The results of this trial demonstrate that in patients with
hypertension and diabetic nephropathy, a telmisartan-based
regimen is superior to a losartan-based regimen for reducing
proteinuria, given similar levels of blood pressure reduction
at 1 year. This change in proteinuria was based on a change in
spot urine protein:creatinine. This method overcomes
the drawbacks of 24-h urine collection12 and correlates with
such values in different patient groups;13,14 thus, it is a
recommended method for clinical trials.15,16
There are many factors that affect proteinuria and may
have influenced the results, although most of those did not
account for differences seen in this trial. One possible factor
that could have affected proteinuria is a disproportionate
increase in dietary sodium intake in one group, since this is
known to blunt the antiproteinuric effects of the renin–
angiotensin system blockers.17 However, we detected no
differences between groups in sodium excretion as assessed
by spot urinary sodium:creatinine ratio at any time point
where proteinuria was assessed. Thus, in this study, changes
in proteinuria cannot be attributed to differences in dietary
sodium.
Another possible explanation for these between-group
differences in proteinuria could relate to a lower blood
pressure favoring one group. Differences in diastolic blood
pressure were not present at any time during the trial. A trend
for a lower systolic pressure, however, was present in the
telmisartan group early in the trial, but failed to reach
significance at trial end. Moreover, the greatest difference in
systolic blood pressure was noted on day 56, where the
difference between groups was 2.9 mm Hg. At every other
time point, non-significant differences of o2 mm Hg in
systolic pressure were observed. There are also no outcome
trial data to support the concept that a 2- or 3-mm Hg
difference in systolic blood pressure translates into protei-
nuria differences. Data from the Captopril trial demonstrated
that a 4-mm Hg difference in systolic blood pressure was
significant between the groups and translated into a
proteinuria difference.18 Thus, since the magnitude of blood
pressure change in this trial is less than that, it probably does
not account for this difference. An additional issue related to
blood pressure lowering maybe the type of agents added to
one group favoring further reduction in proteinuria. This was
also not the case, since all additional antihypertensive agents
were used to a similar extent between the groups.
Another possible explanation for differences between
groups relates to the in vitro demonstration that telmisartan
stimulates peroxisome proliferator-activated receptor-g acti-
vity. Such agents used for diabetes treatment also lower
Table 2 | Change from baseline in secondary renal endpoints at 1 year
Endpoint Telmisartan 80-mg regimena Losartan 100-mg regimena P-value
Serum creatinine (mg/dl) 15% (12%, 18%) 15% (12%, 18%) 0.8950
eGFR (ml/min/1.73 m2) –6.49 (–7.56, –5.42) –6.50 (–7.56, –5.43) 0.9913
Serum aldosterone (ng/dl) –23% (–29%, –18%) –17% (–23%, –11%) 0.0746
C-reactive protein (mg/dl) –6% (–15%, 4%) 1% (–9%, 13%) 0.2777
eGFR, estimated glomerular filtration rate.
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Telmisartan (N=407) Losartan (N=417)
Figure 2 | Changes in urinary sodium excretion as assessed by
spot sodium:creatinine at each time point when proteinuria




























Telmisartan (N=414) Losartan (N=427)
Figure 3 | Changes in systolic and diastolic blood pressure in
each group. The values represent mean±s.d.s at each time
point.
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proteinuria and blood pressure independent of other
antihypertensive agents.19 Unfortunately, the activity of
the peroxisome proliferator-activated receptor-g observed
in vitro with telmisartan has not been shown to translate into
any clinically apparent effect on insulin resistance.20
Angiotensin-1-receptor binding differences between ARBs
could also be conjectured to account for differences in
outcome, although we did not measure such binding in this
trial. It is clear that telmisartan has a higher affinity for the
angiotensin-1 receptor and has a significantly greater
percentage of binding compared with losartan.21,22 Whether
this translates into a better antiproteinuric effect, however,
remains to be proven.
Other factors known to affect proteinuria, such as a
greater reduction in estimated glomerular filtration rate or
serum aldosterone were also not different between groups.
Additionally, dropout rates were similar between groups due
to the incidence of adverse events. As an example, the
incidence of hyperkalemia defined as a serum potassium of
45.5 mEq/l between groups was 1.8% for the study overall,
with no difference between groups. Thus, both telmisartan
and losartan were relatively well tolerated and safe. It,
therefore, appears that there is no clear explanation for these
proteinuria differences.
Losartan has approval by the Food and Drug Adminis-
tration for slowing diabetic nephropathy, based on the results
of the Reduction of Endpoints in NIDDM with the
Angiotensin II Antagonist Losartan (RENAAL) study.23 In
the RENAAL study, proteinuria was reduced by 29% at 6
months and correlated with significant slowing of nephro-
pathy progression compared with placebo.24 Moreover, post
hoc analysis of the RENAAL trial showed that losartan-
induced changes in proteinuria were more predictive of renal
outcomes than blood pressure changes.25 In this study, the
proteinuria reduction observed with the losartan regimen
was 21.4 vs 29.8% with a telmisartan regimen. In both
treatment groups, the greatest reduction in proteinuria was
apparent during the first 26 weeks and persisted for the
remainder of the trial. Similar trends were also observed for
albuminuria. In a separate study, the rate of progression from
micro- to macro-albuminuria in patients with type-2
diabetes was reduced by telmisartan.26 This anti-albuminuric
effect of telmisartan was independent of blood pressure
level, as transition rates were reduced in both hypertensive
(4140/90 mm Hg) and normotensive patients.
We conclude that a telmisartan-based regimen for blood
pressure reduction provides robust antiproteinuric effect in
hypertensive patients with nephropathy-associated type-2
diabetes. This antiproteinuric effect is greater than a losartan-
based regimen at levels of blood pressure that were not
different. Based on available trial data, this difference in
antiproteinuric effect may translate into better renal and
cardiovascular outcomes. Long-term outcome studies, such
as ONgoing Telmisartan Alone and in combination with
Ramipril Global Endpoint Trial (ONTARGET), will demon-
strate whether the antiproteinuric effect of telmisartan is




This is a prospective, randomized, double-blind, double-dummy,
forced-titration, multicenter, parallel-group study. After a 4-week
placebo washout period, with discontinuation of any ARB,
angiotensin-converting enzyme inhibitor, or direct vasodilator,
eligible patients were randomized to telmisartan or losartan
treatment. During the first 2 weeks, the once-daily dose of
telmisartan was 40 mg and 50 mg for losartan. For the remaining
50 weeks, the doses of telmisartan and losartan were 80 and 100 mg/
day, respectively. Additional antihypertensive medication (excluding
other ARBs, angiotensin-converting enzyme inhibitors, or direct
vasodilators) could be given following forced titration to achieve the
blood pressure targets (o130/80 mm Hg).
Study population
Inclusion criteria were as follows: (1) age 21–80 years, (2) history
of type-2 diabetes mellitus, (3) total hemoglobin A1c p10%,
(4) serum creatininep3 mg/dl (women) orp3.2 mg/dl (men), and
(5) first-morning spot UPC X700 mg/g creatinine. Note that
urinalysis was performed to eliminate the possibility of other
abnormalities such as hematuria and so on. Lastly, mean systolic
blood pressure and/or diastolic blood pressure 130/80 mm Hg, or
receiving antihypertensive(s) for hypertension. If systolic blood
pressure exceeded 160 mm Hg or diastolic blood pressure exceeded
110 mm Hg at any time, patients were automatically withdrawn.
Blood pressure was assessed using the American Heart Association
criteria.9 Exclusion criteria included (1) women who were nursing,
pregnant, or surgically sterile and not using effective contraception;
(2) 435% increase in serum creatinine during the washout period
or serum potassium level 45 mEq/l; (3) non-diabetic renal disease;
(4) clinically significant heart disease, stroke, renal artery stenosis,
hepatic dysfunction, or electrolyte imbalance; (5) known hyper-
sensitivity to any component of the study medications; and
(6) requiring chronic immunosuppressive therapy.
Study endpoints
The primary efficacy endpoint was change from baseline in early-
morning spot UPC. Secondary renal endpoints included change
from baseline in early-morning spot albumin:creatinine; estimated
glomerular filtration rate, using the modified MDRD equation;28
and early-morning spot sodium:creatinine. Also, a composite of a
doubling of serum creatinine concentration, end-stage renal disease
(need for long-term dialysis, renal transplantation, or a serum
creatinine X6 mg/dl), or death was assessed. Other secondary
endpoints were change from baseline in systolic blood pressure and
diastolic blood pressure, high-sensitivity C-reactive protein, and
serum aldosterone. Adverse events and safety laboratories were also
monitored. All samples were stored at –20 1C and dispatched to a
central laboratory (Quest Diagnostics Clinical Trials, Van Nuys, CA,
USA) for analysis.
Statistical analysis
The power of the study was assessed assuming a standard deviation
of the change from baseline in UPC from similar cohorts observed
in different trials, and expected to be approximately 2 mg/g
creatinine.29,30 Thus, 340 patients per treatment arm would yield
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90% power at the 5% (two-sided) level of significance to detect a
between group difference of 0.5 mg/g creatinine in UPC in the
reduction from baseline. We further assumed, however, a 15%
dropout rate with no final UPC measurement; consequently, 400
patients per treatment arm were required to identify any differences
in efficacy.
Efficacy was determined in patients with a baseline and X1 on-
treatment renal efficacy parameter measurement, with last observa-
tion carried forward. For the primary endpoint, an analysis of
covariance that included treatment and pooled center as class effects,
with baseline as a covariate, was performed on the log-transformed
data. Mean values were expressed as geometric means (geometric
coefficient of variation, %). Significance of changes from baseline
within treatment groups and differences between treatment groups
were established by two-sided 95% confidence interval and P-value.
The same procedure was used for all secondary renal endpoints
other than estimated glomerular filtration rate, which were
expressed as arithmetic mean and standard deviation. Changes in
blood pressure were expressed as mean values and standard error.
Time-to-event data were analyzed by Kaplan–Meier method, with
treatment groups being compared by means of log-rank test.
Baseline demographics were summarized descriptively for each
treatment.
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